Statin monotherapy attenuates renal injury in a salt-sensitive hypertension model of renal disease

Nephron - Physiology

Volumn 101, Issue 4, 2005, Pages

  Vieira Jr , J M ^a,b   Rodrigues, L T ^a   Mantovani, E ^a   Delle H ^a   Mattar, A L ^a   Malheiros, D M A C ^a   Noronha, I L ^a   Fujihara, C K ^a   Zatz, R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Hypertension; Interstitial fibrosis; Monocyte chemoattractant protein 1; Nitric oxide; p21; Renal inflammation; Simvastatin; Transforming growth factor

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYCLINE; FIBRONECTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYMPHOTOXIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; PROTEIN P21; PROTEIN P27; SIMVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFICACY; FIBROSING ALVEOLITIS; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY INTERSTITIUM; LYMPHOCYTE; MACROPHAGE; MALE; MONOTHERAPY; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RAT STRAIN; RENOVASCULAR HYPERTENSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALT INTAKE; WESTERN BLOTTING;

ALBUMINURIA; ANIMALS; CELL DIVISION; CHEMOKINE CCL2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EXTRACELLULAR MATRIX; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, RENAL; LYMPHOCYTES; MACROPHAGES; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; RATS; RATS, WISTAR; RNA, MESSENGER; SIMVASTATIN; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA;

EID: 27544470302     PISSN: 16602137     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087576     Document Type: Article

References (40)

1. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-1650.
2. Farmer JA: Pleiotropic effects of statins. Curr Atheroscler Rep 2000;2:208-217.
3. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr: Measurement of C-reactive protein for the targeting of statins therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965.
4. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ: Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998;339:1972-1978.
5. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten N, Fichtlscherer S, Martin H, Zeiher AM: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001;108:391-397.
6. Kip1. J Am Soc Nephrol 1998;9:2235-2243.
7. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D, Peterson L, Detmers PA, Chao YS, Wright SD: Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001;21:115-121.
8. Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, Abbate M, Remuzzi G: Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 2002;61:1635-1645.
9. Rubin R, Silbiger S, Sablay L, Neugarten J: Combined antihypertensive and lipid-lowering therapy in experimental glomerulonephritis. Hypertension 1994;23:92-95.
10. Park JK, Muller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, Bieringer M, Schafer O, Lindschau C, Schneider W, Ganten D, Luft FC, Haller H: Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int 2000;58:1420-1430.
11. Wilson TW, Alonso-Galicia M, Roman RJ: Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 1998;31:225-231.
12. Jiang J, Roman RJ: Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997;30:968-974.
13. Usui H, Shikata K, Matsuda M, Okada S, Ogawa D, Yamashita T, Hida K, Satoh M, Wada J, Makino H: HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 2003;18:265-272.
14. Li C, Yang CW, Park JH, Lim SW, Sun BK, Jung JY, Kim SB, Kim YS, Kim J, Bang BK: Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol 2004;286:F46-F57.
15. WAF/CIP1 in human prostate carcinoma cells. J Biol Chem 1998;273:10618-10623.
16. (WAF1/CIP1) gene ameliorates progression to chronic renal failure. Proc Natl Acad Sci USA 1999;96:10830-10835.
17. WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int 1999;56:1691-1699.
18. Mattar AL, Fujihara CK, Andreoli N, Malheiros DMAC, Noronha IL, Zatz R: Renal interstitial expression of angiotensin II and the AT1 receptor parallels renal injury in the chronic nitric oxide inhibition model. J Am Soc Nephrol 2001;12:820A.
19. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R: Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 1992;20:298-303.
20. Fujihara CK, Malheiros DM, Zatz R, Noronha ID: Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998;54:1510-1519.
21. Fujihara CK, Malheiros DMAC, Noronha IL, De Nucci G, Zatz R: Mycophenolate mofetil reduces renal injury in the chronic nitric oxide synthase inhibition model. Hypertension 2001;37:170-175.
22. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
23. Giachelli CM, Pichler R, Lombardi D, Denhardt DT, Alpers CE, Schwartz SM, Johnson RJ: Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. Kidney Int 1994;45:515-524.
24. Haller H, Park JK, Dragun D, Lippoldt A, Luft FC: Leukocyte infiltration and ICAM-1 expression in two-kidney one-clip hypertension. Nephrol Dial Transplant 1997;12:899-903.
25. Baylis C, Mitruka B, Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992;90:278-281.
26. Zatz R, Baylis C: Chronic nitric oxide inhibition model six years on. Hypertension 1998;32:958-964.
27. Massy ZA, Guijarro C: Statins: effects beyond cholesterol lowering. Nephrol Dial Transplant 2001;16:1738-1741.
28. Eddy AA, Giachelli CM: Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 1995;47:1546-1557.
29. 2 through a PKC-dependent pathway. J Am Soc Nephrol 2002;13:1179-1189.
30. Wolf G, Jocks T, Zahner G, Panzer U, Stahl RA: Existence of a regulatory loop between MCP-1 and TGF-β in glomerular immune injury. Am J Physiol 2002;283:F1075-F1084.
31. Shimizu H, Maruyama S, Yuzawa Y, Kato T, Miki Y, Suzuki S, Sato W, Morita Y, Maruyama H, Egashira K, Matsuo S: Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria. J Am Soc Nephrol 2003;14:1496-1505.
32. 1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996;271:17779-17784.
33. Yamamoto T, Eckes B, Krieg T: Effect of interleukin-10 on the gene expression of type I collagen, fibronectin, and decorin in human skin fibroblasts: differential regulation by transforming growth factor-β and monocyte chemoattractant protein-1. Biochem Biophys Res Commun 2001;281:200-205.
34. Viedt C, Orth SR: Monocyte chemoattractant protein-1 in the kidney: Does it more than simply attract monocytes? Nephrol Dial Transplant 2002;17:2043-2047.
35. Harper JW: Cyclin-dependent kinase inhibitors. Cancer Surv 1997;29:91-107.
36. Shankland SJ, Wolf G: Cell cycle regulatory proteins in renal disease: role in hypertrophy, proliferation, and apoptosis. Am J Physiol 2000;278:F515-F529.
37. WAF1/CIP1/SDI1 in kedney tubule cells affects the course of cisplatin-induced acute renal failure. J Clin Invest 1998;101:777-782.
38. WAF1/CIP1 on the course of ischemic acute renal failure. Kidney Int 2001;60:2164-2172.
39. (Waf1/Cip1). Atherosclerosis 2002;161:105-112.
40. (WAF1/CIP1) in tubulointerstitial fibrosis of aging rats. Exp Mol Pathol 2001;70:43-53.